Perception Versus Reality?: Virtual Crossmatch—How to Overcome Some of the Technical and Logistic Limitations

The goal of this work was to evaluate concordance between (a) actual flow cytometric crossmatch (FCXM) that is performed by the OPO laboratory servicing our transplant center and (b) virtual XM (vXM) prediction based on antibody identification by solid‐phase methods performed in our laboratory.

[1]  V. D’Agati,et al.  Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. , 2008, Transplant immunology.

[2]  J. Friedewald,et al.  Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience , 2008, Transplantation.

[3]  K. Nelson,et al.  19-OR: Comparing the UNOS/OPTN CPRA system vs. local CPRA system , 2008 .

[4]  L. Hunsicker,et al.  47-W: A case of antibody mediated rejection from anti-donor HLA-Cw antibody , 2008 .

[5]  S. Jordan,et al.  Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy , 2008, Transplantation.

[6]  A. Zachary.  Antibody monitoring: a solid approach to predicting clinical outcome. , 2008, Transplantation.

[7]  P. Sinnott,et al.  Pretransplant Donor-Specific Antibodies in Cytotoxic Negative Crossmatch Kidney Transplants: Are They Relevant? , 2008, Transplantation.

[8]  M. Christiaans,et al.  Clinical Relevance of Pretransplant Donor-Directed Antibodies Detected by Single Antigen Beads in Highly Sensitized Renal Transplant Patients , 2008, Transplantation.

[9]  S. Vaidya.  Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches , 2008, Transplantation.

[10]  F. Gao,et al.  Anti-MHC Class I Antibody Activation of Proliferation and Survival Signaling in Murine Cardiac Allografts1 , 2008, The Journal of Immunology.

[11]  D. Nochy,et al.  Clinical Relevance of Preformed HLA Donor‐Specific Antibodies in Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  David Briggs,et al.  Blood Levels of Donor-Specific Human Leukocyte Antigen Antibodies After Renal Transplantation: Resolution of Rejection in the Presence of Circulating Donor-Specific Antibody , 2007, Transplantation.

[13]  S. Mulgaonkar,et al.  Renal Transplantation in Patients With Pre‐Transplant Donor‐Specific Antibodies and Negative Flow Cytometry Crossmatches , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  S. Berger,et al.  Practical application of the virtual crossmatch , 2007, Pediatric transplantation.

[15]  D. Segev,et al.  Subclinical Acute Antibody‐Mediated Rejection in Positive Crossmatch Renal Allografts , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  M. Mihatsch,et al.  Pretransplant Risk Assessment in Renal Allograft Recipients Using Virtual Crossmatching , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  B. Susskind,et al.  Prediction of Crossmatch Outcome of Highly Sensitized Patients by Single and/or Multiple Antigen Bead Luminex Assay , 2006, Transplantation.

[18]  M. Stegall,et al.  Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  E. Reed,et al.  Anti-HLA Antibodies Can Induce Endothelial Cell Survival or Proliferation Depending on their Concentration , 2006, Transplantation.

[20]  E. Cantu,et al.  Role of Flow Cytometry to Define Unacceptable HLA Antigens in Lung Transplant Recipients with HLA-Specific Antibodies , 2006, Transplantation.

[21]  K. Mussatto,et al.  The virtual crossmatch – A screening tool for sensitized pediatric heart transplant recipients , 2006, Pediatric transplantation.

[22]  L. Ratner,et al.  Overcoming Immunologic Incompatibility: Transplanting the Difficult to Transplant Patient , 2005, Seminars in dialysis.

[23]  P. Terasaki,et al.  HLA antibody identification with single antigen beads compared to conventional methods. , 2005, Human immunology.

[24]  J. Platt,et al.  Acute Vascular Rejection and Accommodation: Divergent Outcomes of the Humoral Response to Organ Transplantation , 2004, Transplantation.

[25]  M. Stegall,et al.  Persistence of Low Levels of Alloantibody after Desensitization in Crossmatch-Positive Living-Donor Kidney Transplantation , 2004, Transplantation.

[26]  I. Doxiadis,et al.  HLA-CW SPECIFIC ANTIBODIES AND KIDNEY TRANSPLANTATION , 2004 .

[27]  M. Fishbein,et al.  Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. , 2004, Human immunology.

[28]  P. Nickerson,et al.  Pre‐Transplant Assessment of Donor‐Reactive, HLA‐Specific Antibodies in Renal Transplantation: Contraindication vs. Risk , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  A. Matas,et al.  Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation , 2003, Transplantation.

[30]  P. Terasaki,et al.  Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities , 2003, Transplantation.

[31]  G. Zibari,et al.  Conundrums with FlowPRA™ beads , 2002, Clinical transplantation.

[32]  P. Nickerson,et al.  Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. , 2001, Journal of the American Society of Nephrology : JASN.

[33]  G. Remuzzi,et al.  Challenges to achieving clinical transplantation tolerance. , 2001, The Journal of clinical investigation.

[34]  R. Lechler,et al.  Transplant Accommodation in Highly Sensitized Patients: A Potential Role for Bcl‐xL and Alloantibody , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  R. Howard,et al.  OUTCOME OF KIDNEY TRANSPLANTS IN PATIENTS KNOWN TO BE FLOW CYTOMETRY CROSSMATCH POSITIVE1 , 2001, Transplantation.

[36]  S. Gruber,et al.  Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. , 1999, Transplantation.

[37]  Cecka Jm,et al.  Crossmatch tests--an analysis of UNOS data from 1991-2000. , 2001 .

[38]  J. Cecka,et al.  Crossmatch tests--an analysis of UNOS data from 1991-2000. , 2001, Clinical transplants.